Autologous Peripheral Blood Mononuclear Cell (Pbmc)-Derived T Lymphocytes Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector Encodinga Chimeric Antigen Receptor (Car) Targeting Two Epitopes Of The Human B Cell Maturation Antigen (Bcma) Under The Control Of A Human Elongation Factor 1 Alpha (Ef1.Alpha.) Promoter The Coding Sequence Comprises A Human Cd8 Alpha Signal Peptide (Cd8.Alpha. Sp), A Bcma Targeting Domain Consisting Of Two Variable Heavy Chain-Only Antibodies (Vhh1 And Vhh2) Targeting Two Distinct Bcma Epitopes, A Human Cd8 Alpha Hinge And Transmembrane Domain (Cd8.Alpha. Hinge + Tm), A Human Cd137 Cytoplasmic Domain (4-1Bb) And A Human Cd3 Zeta Cytoplasmic Domain (Cd3.Zeta.). The Vector Genome Contains A Chimeric Rous Sarcoma Virus (Rsv)/Truncated 5'Ltr And A Self-Inactivating 3'Ltr-Sin (.Delta.-U3)
Plasma Cell Myeloma
Explore 475 assets in Plasma Cell Myeloma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Janssen Research & Development, LLC
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04133636CT.gov A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03548207CT.gov A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma | — | Completed | — | — | — |
NCT04452994CT.gov Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plasma Cell Myeloma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Autologous Peripheral Blood Mononuclear Cell (Pbmc)-Derived T Lymphocytes Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector Encodinga Chimeric Antigen Receptor (Car) Targeting Two Epitopes Of The Human B Cell Maturation Antigen (Bcma) Under The Control Of A Human Elongation Factor 1 Alpha (Ef1.Alpha.) Promoter The Coding Sequence Comprises A Human Cd8 Alpha Signal Peptide (Cd8.Alpha. Sp), A Bcma Targeting Domain Consisting Of Two Variable Heavy Chain-Only Antibodies (Vhh1 And Vhh2) Targeting Two Distinct Bcma Epitopes, A Human Cd8 Alpha Hinge And Transmembrane Domain (Cd8.Alpha. Hinge + Tm), A Human Cd137 Cytoplasmic Domain (4-1Bb) And A Human Cd3 Zeta Cytoplasmic Domain (Cd3.Zeta.). The Vector Genome Contains A Chimeric Rous Sarcoma Virus (Rsv)/Truncated 5'Ltr And A Self-Inactivating 3'Ltr-Sin (.Delta.-U3) (this asset) | Janssen Research & Development, LLC | P2 | CCC · 53 |
| Hyaluronidase Fihj | Massachusetts General Hospital | P4 | BBB |
| Filanesib | PETHEMA Foundation | P2 | BBB |
| Vincristine Sulfate | Roswell Park Cancer Institute | P3 | BBB |
| Cyclosporin A | Seoul National University Hospital | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | University of Birmingham | P4 | BBB |
| Epoetin Alfa | Mayo Clinic | P3 | BB |
| Arsenic Trioxide | Duke University | P2 | BB |
| Sorafenib | OHSU Knight Cancer Institute | P2 | BB |
+42 more in the Plasma Cell Myeloma cohort
Other indications for Autologous Peripheral Blood Mononuclear Cell (Pbmc)-Derived T Lymphocytes Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector Encodinga Chimeric Antigen Receptor (Car) Targeting Two Epitopes Of The Human B Cell Maturation Antigen (Bcma) Under The Control Of A Human Elongation Factor 1 Alpha (Ef1.Alpha.) Promoter The Coding Sequence Comprises A Human Cd8 Alpha Signal Peptide (Cd8.Alpha. Sp), A Bcma Targeting Domain Consisting Of Two Variable Heavy Chain-Only Antibodies (Vhh1 And Vhh2) Targeting Two Distinct Bcma Epitopes, A Human Cd8 Alpha Hinge And Transmembrane Domain (Cd8.Alpha. Hinge + Tm), A Human Cd137 Cytoplasmic Domain (4-1Bb) And A Human Cd3 Zeta Cytoplasmic Domain (Cd3.Zeta.). The Vector Genome Contains A Chimeric Rous Sarcoma Virus (Rsv)/Truncated 5'Ltr And A Self-Inactivating 3'Ltr-Sin (.Delta.-U3)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Extramedullary Plasmacytoma | — | P1 | CC · 43 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Autologous Peripheral Blood Mononuclear Cell (Pbmc)-Derived T Lymphocytes Transduced Ex Vivo With A Non-Replicating, Self-Inactivating (Sin) Lentiviral Vector Encodinga Chimeric Antigen Receptor (Car) Targeting Two Epitopes Of The Human B Cell Maturation Antigen (Bcma) Under The Control Of A Human Elongation Factor 1 Alpha (Ef1.Alpha.) Promoter The Coding Sequence Comprises A Human Cd8 Alpha Signal Peptide (Cd8.Alpha. Sp), A Bcma Targeting Domain Consisting Of Two Variable Heavy Chain-Only Antibodies (Vhh1 And Vhh2) Targeting Two Distinct Bcma Epitopes, A Human Cd8 Alpha Hinge And Transmembrane Domain (Cd8.Alpha. Hinge + Tm), A Human Cd137 Cytoplasmic Domain (4-1Bb) And A Human Cd3 Zeta Cytoplasmic Domain (Cd3.Zeta.). The Vector Genome Contains A Chimeric Rous Sarcoma Virus (Rsv)/Truncated 5'Ltr And A Self-Inactivating 3'Ltr-Sin (.Delta.-U3) in Plasma Cell Myeloma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/autologous-peripheral-blood-mononuclear-cell-pbmc-derived-t-lymphocytes-transduced-ex-vivo-with-a-non-replicating-self-inactivating-sin-lentiviral-vector-encodinga-chimeric-antigen-receptor-car-targeting-two-epitopes-of-the-human-b-cell-maturation-antigen-bcma-under-the-control-of-a-human-elongation-factor-1-alpha-ef1alpha-promoter-the-coding-sequence-comprises-a-human-cd8-alpha-signal-peptide-cd8alpha-sp-a-bcma-targeting-domain-consisting-of-two-variable-heavy-chain-only-antibodies-vhh1-and-vhh2-targeting-two-distinct-bcma-epitopes-a-human-cd8-alpha-hinge-and-transmembrane-domain-cd8alpha-hinge-tm-a-human-cd137-cytoplasmic-domain-4-1bb-and-a-human-cd3-zeta-cytoplasmic-domain-cd3zeta-the-vector-genome-contains-a-chimeric-rous-sarcoma-virus-rsvtruncated-5ltr-and-a-self-inactivating-3ltr-sin-delta-u3-plasma-cell-myeloma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →